TREX WIND-DOWN, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-12-14: Form 8-K; Period of report 2022-12-14; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2022-12-09: Form 8-K; Period of report 2022-12-08; Description 8.01 Other Events; Details 8.01.
- 2022-11-14: Form 8-K; Period of report 2022-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-11-09: Form 8-K; Period of report 2022-11-07; Description 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 3.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-12-14 | 8-K | 2022-12-14 | 7.01 Regulation FD Disclosure | 7.01 On December 14, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company will host a virtual investor Business Briefing with Q&A on December 20, 2022 at 10:30 a.m. at https://us06web.zoom.us/webinar/register/WN_x5301NsoR0SdymR2s5D7bw. | form8-k.htm |
| 2022-12-09 | 8-K | 2022-12-08 | 8.01 Other Events | 8.01 On December 9, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that on December 8, 2022, the Company received a letter from The NYSE American LLC (the “NYSE American”) stating that the Company had regained compliance with the NYSE American’s continued listing standards. | tmbr-20221208x8k.htm |
| 2022-11-14 | 8-K | 2022-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other information for the quarter ended September 30, 2022. | tmbr-20221114x8k.htm |
| 2022-11-09 | 8-K | 2022-11-07 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.03 The information contained in Item 5.03 below is incorporated by reference into this Item 3.03. | tmbr-20221107x8k.htm |
| 2022-11-08 | 8-K | 2022-11-07 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 On November 7, 2022, Timber Pharmaceuticals, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). 7.01 The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing. | tmbr-20221107x8k.htm |
| 2022-11-03 | 8-K | 2022-11-03 | 8.01 Other Events | 8.01 On November 3, 2022, Timber Pharmaceuticals, Inc. (the “Company”) announced that trading of its shares of common stock has been halted by New York Stock Exchange (“NYSE” or the “Exchange”) due to its low trading price on November 1, 2022. | form8-k.htm |
| 2022-10-25 | 8-K | 2022-10-25 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On October 25, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the European Medicines Agency (“EMA”) has granted orphan designation for TMB-001 for the treatment of autosomal recessive congenital ichthyosis (“ARCI”). 8.01 On October 25, 2022, the Company announced that the EMA has granted orphan designation for TMB-001 for the treatment of ARCI. | tmbr-20221025x8k.htm |
| 2022-10-03 | 8-K | 2022-10-03 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 1.01 On October 3, 2022, Timber Pharmaceuticals, Inc. (the “Company” or “Timber”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional accredited investors (the “Investors”) to sell, in a registered direct offering (the “Registered Offering”) (i) 13,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) Series 1 common warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock (the “Series 1 Warrants”). 3.02 The information contained above in Item 1.01 related to the Concurrent Private Placement Offering, Series B Preferred Stock and the Series 2 Warrants is hereby incorporated by reference into this Item 3.02. 3.03 The disclosure required by this Item and included in Item 5.03 of this Current Report is incorporated herein by reference. 5.03 On October 3, 2022, the Company filed a Certificate of Designation with the Secretary of State for the State of Delaware (the “Series B Certificate of Designation”) designating 13,000 shares out of the authorized but unissued shares of its preferred stock as Series B Preferred Stock. 8.01 On October 3, 2022, the Company issued a press release announcing that it had commenced the Offerings. | tmbr-20221003x8k.htm |
| 2022-09-12 | 8-K | 2022-09-12 | 7.01 Regulation FD Disclosure | 7.01 On September 12, 2022, Timber Pharmaceuticals, Inc. posted presentation materials (the “Investor Presentation”) on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. | tmbr-20220912x8k.htm |
| 2022-09-02 | 8-K | 2022-09-02 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 As a result of the previously disclosed public offering, which closed on August 8, 2022, Timber Pharmaceuticals, Inc. (the “Company”) has stockholders’ equity in excess of $4.0 million as of September 2, 2022. | tmbr-20220902x8k.htm |
| 2022-08-29 | 8-K | 2022-08-23 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 On August 23, 2022, Timber Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American” or the “Exchange”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of common stock have been selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. 8.01 On August 29, 2022, the Company issued a press release disclosing receipt of the Letter. | tmbr-20220823x8k.htm |
| 2022-08-12 | 8-K | 2022-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other information for the quarter ended June 30, 2022. | tmbr-20220811x8k.htm |
| 2022-08-08 | 8-K | 2022-08-04 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On August 4, 2022, the Company issued a press release announcing the pricing of the Offering. | tmbr-20220804x8k.htm |
| 2022-08-02 | 8-K | 2022-07-27 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Letter Agreement, Warrant and underlying warrant shares is hereby incorporated by reference into this Item 3.02. | tmbr-20220727x8k.htm |
| 2022-07-26 | 8-K | 2022-07-20 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On July 22, 2022, the Subsidiary provided written notice to AFT Pharmaceuticals Limited (“AFT”) of its decision to terminate the License Agreement, dated as of July 5, 2019, by and between the Subsidiary and AFT (the “License Agreement”) because the Company believes there is no longer a commercially reasonable path to approval and commercialization for TMB-002 in the United States for facial angiofibromas associated with tuberous sclerosis complex. 2.02 ● Net loss for the three and six months ended June 30, 2022 is expected to be approximately $9.4 million and $12.5 million, respectively, compared to $3.0 million and $4.8 million for the three and six months entered June 30, 2021, respectively. 8.01 On June 30, 2022, the Company received a notice of allowance from the United States Patent and Trademark Office for a patent application covering TMB-001 (Application Number: 16/875,710) covering claims to the uses and methods of treating congenital ichthyosis and administering isotretinoin. | tmbr-20220720x8k.htm |
| 2022-06-23 | 8-K | 2022-06-23 | 8.01 Other Events | 8.01 On June 23, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the first patients have been enrolled in the Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis. | tmbr-20220623x8k.htm |
| 2022-06-10 | 8-K | 2022-06-10 | 7.01 Regulation FD Disclosure | 7.01 On June 10, 2022, Timber Pharmaceuticals, Inc. posted presentation materials (the “Investor Presentation”) on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. | tmbr-20220610x8k.htm |
| 2022-06-07 | 8-K | 2022-06-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 3, 2022, Timber Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | tmbr-20220607x8k.htm |
| 2022-05-31 | 8-K | 2022-05-31 | 8.01 Other Events | 8.01 On May 31, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, for the treatment of congenital ichthyosis. | tmbr-20220531x8k.htm |
| 2022-05-12 | 8-K | 2022-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other information for the quarter ended March 31, 2022. | tmbr-20220512x8k.htm |
| 2022-04-28 | 8-K | 2022-04-28 | 8.01 Other Events | tmbr-20220428x8k.htm | |
| 2022-04-25 | 8-K | 2022-04-25 | 8.01 Other Events | 8.01 Timber Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, is providing an update on its clinical development programs. | tmbr-20220425x8k.htm |
| 2022-04-11 | 8-K | 2022-04-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 Effective April 10, 2022, the Board of Directors (the “Board”) of Timber Pharmaceuticals, Inc. (the “Company”) adopted an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws, (the “Bylaws”), amending Section 7 of Article I thereof to decrease the quorum requirement for stockholder meetings from a majority to thirty-four (34%) percent of the voting power of the capital stock of the Company issued and outstanding and entitled to vote, present in person or represented by proxy, at a meeting. | tmbr-20220410x8k.htm |
| 2022-04-01 | 8-K | 2022-03-31 | 2.02 Results of Operations and Financial Condition | 2.02 On March 31, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other information for the year ended December 31, 2021. | tmbr-20220331x8k.htm |
| 2022-03-25 | 8-K | 2022-03-25 | 8.01 Other Events | 8.01 On March 25, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a late-breaking presentation of a sub-analysis of the Company’s Phase 2b CONTROL study that evaluated TMB-001, the Company’s topical pharmaceutical composition of isotretinoin, for the treatment of moderate to severe subtypes of congenital ichthyosis, to be presented at the American Academy of Dermatology 2022 Annual Meeting. | form8-k.htm |
| 2022-02-03 | 8-K | 2022-02-03 | 8.01 Other Events | 8.01 On February 3, 2022, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration for the Company’s topical pharmaceutical composition of isotretinoin, for the treatment of moderate to severe subtypes of congenital ichthyosis. | tmbr-20220203x8k.htm |
| 2022-01-18 | 8-K | 2022-01-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 11, 2022, Timber Pharmaceuticals, Inc. (the “Company”) received notice from Zachary Rome, Chief Operating Officer, Executive Vice President and member of the Company’s Board of Directors (the “Board”), that he will step down and resign as an officer of the Company effective March 4, 2022. | tmbr-20220111x8k.htm |